Enicepatide Dosage, half-life & reference guide
Also known as CT-388 · CT388 · RO7795068
Reviewed 1 studyEvidence: ModeratePublished by PepVault
A weekly GLP-1 and GIP dual agonist from Roche, the same two receptors as tirzepatide, built to keep the receptors responsive by avoiding one of their shut-off signals. In its 48-week obesity phase 2 trial, the top 24 mg dose took off about 22.5% more weight than placebo, and the curve had not flattened.
- Studied range
- 4–24 mgstarting dose 2 mg
- How often
- Weekly
- Half-life
- ~5.5 days
- Evidence
- ●●
●Moderate - Route
- SubQ injection
Studied in research — not a recommendation.
How it works.
Once-weekly peptide that switches on both the GLP-1 and the GIP receptors, tirzepatide's pair, with a twist: it is built to trigger the receptors' main signal while barely recruiting beta-arrestin, the protein that pulls receptors inside the cell. The idea is that receptors stay on the surface and keep responding, so the effect lasts. Its half-life in people is about 5 to 6 days. Developed by Carmot Therapeutics and now Roche, in phase 3 since March 2026.
Commonly reported: In trials, GI side effects, mostly mild to moderate, during the step-ups. It is in phase 3 and not approved anywhere.
Half-life & active level
The half-life of Enicepatide is ~5.5 days (measured in people: mean 123–139 hours after single doses; phase 1, Chakravarthy 2026).
Here's how a typical Enicepatide schedule accumulates over four weeks (one-compartment estimate).
An estimate from the half-life above, not a measurement. See your own curve build live in the half-life calculator.

Model. Individual results vary.
Where Enicepatide works.

Appetite & metabolism
In people. At 48 weeks that group lost about 22.5% more weight than placebo, and nearly half lost at least 20% of their weight.
An area lights for what a peptide is used for and what people report, with the evidence beside it. It isn’t a promise that it works there.
Week by week.
What to expect in the first 8 weeks
- Onset
- Days–2 weeks
- Peak effect
- 48 weeks (phase 2 endpoint, no plateau)
- Duration
- Ongoing
Day 1–28 · 2 mgRCT
Two milligrams, the first step
You're on 2 mg, where the higher-dose groups in the phase 2 obesity trial began. Commonly reported: appetite dropping in the first days. In its trials, GI side effects were mostly mild to moderate and came with the step-ups.
The science
CT388-103 (NCT06525935; 469 adults with obesity or overweight without diabetes, 34 US sites): the 12, 16 and 24 mg groups started at 2 mg and stepped up through 4, 8, 12, 16 and 20 mg; the 4 and 8 mg groups started at 4 mg; all reached their top dose within 27 weeks, with delayed steps allowed for tolerability (Roche ADA 2026 poster). Most GI events were mild to moderate (Roche, Jan-27-2026).
Sources- Roche (phase 2 obesity release) (2026)
- Lingvay et al. (ADA poster) (2026)
Updated Nov 2026
Day 29–112 · 8 mgRCT
Through the middle steps
You're at 8 mg, one of the doses the phase 2 trial also tested as a final dose. Commonly reported: a few queasy days after each step, then steadier appetite control. A slower step was allowed in the trial when side effects needed time to settle.
The science
CT388-103 tested final doses of 4, 8, 12, 16 and 24 mg (about 78 people each) against placebo, with a clear dose response for weight (Roche, Jan-27-2026; ADA 2026 poster). Delayed titration was allowed weekly from week 8 for the three highest-dose groups.
Sources- Roche (phase 2 obesity release) (2026)
- Lingvay et al. (ADA poster) (2026)
Updated Nov 2026
Any dayRCT
What Enicepatide is built on
A phase 1 trial with a published paper, and two 48-week phase 2 trials, one in obesity and one in type 2 diabetes, reported by Roche. Phase 3 began in March 2026. It is not approved anywhere.
The science
Discovery and phase 1 (Chakravarthy 2026, Mol Metab; NCT04838405, sponsor Carmot): cAMP-biased at both receptors with minimal internalisation; weight loss in mice and monkeys; in people, single doses of 0.5 to 7.5 mg and four weekly doses of 5 to 12 mg, half-life 123 to 139 h, −4.7% to −8.0% at day 29 vs −0.5% on placebo. Phase 2: CT388-103 (obesity) and CT-388-104 (diabetes). Phase 3: ENITH-1 (NCT07351045, ~2,000, three dosing regimens) and ENITH-2 (NCT07351058), sponsor Hoffmann-La Roche.
Sources- Chakravarthy et al. (2026)
- Roche (phase 2 obesity release) (2026)
- Roche (phase 2 diabetes release) (2026)
Updated Nov 2026
With BPC-157Community
Why people add BPC-157 to a GLP-1
GI side effects come mostly with the step-ups, and BPC-157, first studied as a stomach-protecting peptide, is added to ease them. Commonly reported: smoother step-ups. No trial has tested the pair.
The science
BPC-157's early research was on gastric protection in animal studies (Sikiric 2018 review). No trial has tested it alongside enicepatide or any GLP-1 drug; the pairing comes from community reports.
Sources- Sikiric et al. (2018)
Updated Nov 2026
After week 8
Day 85–336RCT
With type 2 diabetes
In a 48-week trial in type 2 diabetes, the 24 mg dose lowered HbA1c by 2.65 points and weight by about 15.5%. Nine in ten on that dose reached an HbA1c of 6.5% or lower, and few stopped for side effects.
The science
CT-388-104 (NCT06628362; 447 adults with type 2 diabetes and overweight or obesity): at 24 mg, HbA1c −2.65% from 8.1% (−4.13% when baseline was above 8.5%); 90% reached ≤6.5% and 62% below 5.7%; weight −15.5% with no plateau; stopping for side effects 2.0% on enicepatide vs 0.0% on placebo (Roche, Sep-22-2026; topline).
Sources- Roche (phase 2 diabetes release) (2026)
Updated Nov 2026
Day 113–336 · 24 mgRCT
The top dose tested
You're at 24 mg, the highest dose in phase 2. At 48 weeks that group lost about 22.5% more weight than placebo, and nearly half lost at least 20% of their weight. The curve had not flattened by the end.
The science
CT388-103 at 24 mg, week 48: placebo-adjusted −22.5% (efficacy estimand) and −18.3% (treatment-regimen estimand), both p < 0.001; 95.7% reached ≥5% loss, 87% ≥10%, 47.8% ≥20% and 26.1% ≥30%; 54% reached a BMI under 30 vs 13% on placebo; 73% of those with prediabetes returned to normal glucose (Roche, Jan-27-2026). Topline and poster; not yet a paper.
Sources- Roche (phase 2 obesity release) (2026)
Updated Nov 2026
Day 337+Clinical
A long-term medicine, not a course
Worth knowing before you stop: with GLP-1 drugs, coming off usually means regaining most of the loss within about a year and a half. Enicepatide hasn't been tested in a stopping trial, so this is the pattern of other weight drugs. Continue, taper or stop is a call for you and your clinician.
The science
A BMJ meta-analysis found that after stopping semaglutide or tirzepatide, about 9.9 kg came back within the first year, with weight projected back to baseline about 1.5 years after stopping (West 2026). No withdrawal trial of enicepatide has been published.
Sources- West et al. (2026)
Updated Nov 2026
Day 1 is the day you start it.
Phase 1 (Chakravarthy 2026, Mol Metab; NCT04838405), obesity phase 2 (Roche, Jan-27-2026; ADA 2026 poster; NCT06525935), diabetes phase 2 (Roche, Sep-22-2026; NCT06628362), ENITH records on ClinicalTrials.gov. Investigational.
Moderate evidence
Mixing and a typical run.
Example numbers
Reconstitution example
Reconstitute a 10 mg vial of Enicepatide with 2 mL of bacteriostatic water and a 2 mg dose is 40 units on a U-100 syringe, about 5 doses per vial.
- Vial
- 10 mg
- Water
- 2 mL
- Amount
- 2 mg
Draw to40 units
0.5 mL insulin syringe · 50 units
Run notes
- Cycle
- Used continuously, once weekly, in its trials: 48 weeks in both phase 2 trials, with the dose stepped up over as long as 27 weeks. No trial has tested stopping it.Community practice — opinions vary. Not a clinical recommendation.
- Timing
- Once weekly SubQ, same day each week, in its trials. In the obesity phase 2, the higher-dose groups stepped up from 2 mg through 4, 8, 12, 16 and 20 mg to 24 mg, reaching their top dose within 27 weeks, with slower steps allowed for tolerability; the lowest groups started at 4 mg. These are trial schedules, not an approved regimen.
- Route
- SubQ injection
- Stacks
- BPC-157 (GI support)
Safety.
Common side effects
- Nausea
- Constipation
- Diarrhea
- Vomiting
Interactions
No interaction studies have been published. GLP-1 drugs slow stomach emptying, which can change how oral medicines are absorbed. It is a GLP-1 drug itself, so it is not stacked with another one. Roche plans to test it with its amylin drug petrelintide. With insulin or a sulfonylurea, discuss glucose monitoring with your clinician.
Safety notes
Enicepatide has no label: it is still in trials. In the 48-week obesity phase 2 trial, most side effects were GI (nausea, constipation, diarrhea, vomiting) and mild to moderate, in line with the incretin class; 5.9% on enicepatide stopped for side effects vs 1.3% on placebo, and serious events were low and not dose-related, with no grade 4 or 5 events. In the diabetes phase 2 trial, 2.0% stopped for side effects vs 0% on placebo. It is a GLP-1 drug, so the class warnings in GLP-1 labels (including pancreatitis, gallbladder disease and the rodent thyroid C-cell finding) are the ones to read. These are trial findings to review with your clinician.
Goes with.
One question at a time.
Compared with.
Mixing charts by vial size.
Studies, in plain English.
Questions people ask.
What is Enicepatide?
A weekly GLP-1 and GIP dual agonist from Roche, the same two receptors as tirzepatide, built to keep the receptors responsive by avoiding one of their shut-off signals. In its 48-week obesity phase 2 trial, the top 24 mg dose took off about 22.5% more weight than placebo, and the curve had not flattened.
How is Enicepatide dosed in research?
The research range for Enicepatide is 4–24 mg, weekly, with a 2 mg starting dose. Studied in research — not a recommendation.
How long does Enicepatide last?
The half-life of Enicepatide is ~5.5 days (measured in people: mean 123–139 hours after single doses; phase 1, Chakravarthy 2026).
What do people report on Enicepatide?
Commonly reported on Enicepatide: in trials, GI side effects, mostly mild to moderate, during the step-ups. It is in phase 3 and not approved anywhere.
Is Enicepatide safe?
The research basis for Enicepatide is moderate: animal studies + some human data. Common side effects in the library: nausea, constipation, diarrhea and vomiting.
What does Enicepatide stack with?
Common stacks for Enicepatide: BPC-157 (GI support).
Research.
Reference.
- Cadence
Weekly
- Half-life
~5.5 days
~5.5 days (measured in people: mean 123–139 hours after single doses; phase 1, Chakravarthy 2026)
- Research basis
●●
●ModerateAnimal studies + some human data
Reviewed How we check the library
